Vanda Pharmaceuticals Inc.: Vanda's Letter to FDA Commissioner Highlights Faulty ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. As ...
Vanda Pharmaceuticals issues letter to FDA on faulty gastroparesis NDA review
Vanda Pharmaceuticals (VNDA) issued a letter to FDA Commissioner highlighting what the company considers a faulty gastroparesis NDA review.
Malaysian Reserve1 天
Vanda’s Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA ...
Newport Beach Independent1 天
Bariatric Surgeons Face Decline As GLP-1s Gain Ground In Obesity Treatment
Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...
BioSpace21 天
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as ...
(NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, underscores its ...
Johns Hopkins Medicine21 天
Lung Cancer Treatment
Treatment for lung cancer varies according to age, type of cancer, extent of disease, tolerance to medication and patient preference. Treatment options include a combination of surgery, radiation, ...
Nasdaq22 天
Evoke Pharma Addresses FDA Update on Domperidone Supply and Highlights GIMOTI as the Only ...
GIMOTI® (metoclopramide) nasal spray remains the sole FDA-approved treatment for diabetic gastroparesis, providing effective symptom relief and substantial cost savings compared to oral ...
Morningstar22 天
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as ...
As the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults, GIMOTI® (metoclopramide) is uniquely positioned to address the ongoing needs of patients ...